肿瘤细胞治疗研究
FRONTIER PAPERS
近 5 年肿瘤细胞治疗领域的研究论文。默认按评分排序（权威性 + 新鲜度）。
The PDPK1-RSK2 axis as a potential convergent therapeutic vulnerability in B-cell lymphomas.
PDPK1/RSK2 轴在几乎所有 BCL 亚型中均被激活，并可能在疾病发生中发挥重要作用。这表明，尽管各亚型在遗传和表型上存在差异，仍有可能开发出跨亚型有效的治疗方法。靶向一个共享的信号通路可能有助于克服传统精准医学中出现的耐药性，并支持针对罕见病亚型的新疗法开发。然而，由于目前研究仍处于临床前阶段，还需开展更多工作。
Short-term manufacturing of IL-7/CCL19-expressing CAR-T cells enhances and prolongs therapeutic effects in solid tumor models.
IL-15 and IL-21 synergy improves anti-tumor efficacy of iPSC-derived cytotoxic T cells in solid tumors.
Constitutive STAT3 Signaling, in Comparison with STAT5, Enhances CAR T-cell Efficacy and Lowers Systemic Toxicity.
Novel NK cell-like phenotype expressing CCR5 and its ligands elicits tumor-specific acquired immunity to carcinomatous peritonitis via host NK-derived
与 rhIL-2 联用时，exp_GAIA 通过 CCR5-CCL3-NK-IFN- -CD8 通路，将内源性 NK 活性与诱导持久、CD8 + T 细胞依赖性抗肿瘤免疫相结合，并通过 CRT 暴露增强 ICD。这些发现支持将 exp_GAIA+rhIL-2 作为一种新的基于 NK 的策略，用于对实体瘤的持久控制。
Repetitive fasting-refeeding enhances metformin-induced CXCR6+ CD8+ T cell tumor infiltration via VCAM-1 upregulation on normalized vasculature during
Enhancing CAR-T cell activity prediction via fine-tuning protein language models with generated CAR sequences.
我们的发现凸显了将序列增强与 PLMs 微调相结合以推进数据驱动的 CAR-T 细胞设计的潜力。
CAR-T cells co-expressing IL-7 and CCL19 promote epitope spreading to enhance antitumor immunity.
MEMBER ACCOUNT
登录成功会直接打开下一页。
